Core Viewpoint - The company has entered into a CDMO service framework agreement with Lepu Medical, aiming to utilize excess production capacity more effectively and generate additional cash flow for the group [1] Group 1: Agreement Details - The agreement was signed on November 28, 2025, between the company and Lepu Medical [1] - The company and/or its subsidiaries will provide CDMO technical services to Lepu Medical and/or its subsidiaries [1] Group 2: Strategic Implications - The agreement allows the company to better utilize its surplus production capacity when suitable business opportunities arise [1] - The board believes that entering into the CDMO service framework agreement will enhance the overall cash flow for the group [1]

Core Viewpoint - Lepu Biopharma-B (02157.HK) has entered into a CDMO service framework agreement with Lepu Medical, aiming to utilize its excess production capacity more effectively and generate additional cash flow for the group [1] Group 1: Agreement Details - The agreement was signed on November 28, 2025, and involves the provision of CDMO technical services by the company and/or its subsidiaries to Lepu Medical and/or its subsidiaries [1] - The company operates a GMP-compliant bioreactor production line that has been in operation since the end of 2019 [1] Group 2: Production Capabilities - The group has a comprehensive production setup, including upstream antibody raw material production lines, formulation production lines, and other facilities that meet GMP standards, ensuring high-quality drug production [1] - The company has a well-established production management structure and a professional production team with rich experience, complementing its production facilities [1] Group 3: Strategic Implications - The board believes that the CDMO service framework agreement will allow the group to better utilize its excess production capacity, which is essential for meeting its own clinical trial and commercialization needs [1] - The agreement is expected to provide supplementary cash flow to the overall operations of the group [1]

智通财经APP讯，乐普生物-B(02157)发布公告，于2025年11月28日，本公司与乐普医疗订立CDMO服务 框架协议，本公司及/或其附属公司同意向乐普医疗及/或其附属公司提供CDMO技术服务。 考虑到本集团为满足自身临床试验及商业化而对药物生产的需求之外，本集团可在适当的商机出现时更 有效利用富余产能。董事认为，订立CDMO服务框架协议将能更有效利用本集团的富余产能，可为本集 团整体产生补充现金流量。 ...

集团主要从事其候选药物的研发，并拥有及运营一条符合GMP标准的生物反应器生产线，该生产线自 2019年底投入运营。集团配备完善的上下游抗体原液生产线、制剂生产线及其他生产设施。集团的生产 设施符合GMP标准亦证明其药物生产环节为高质量标准。集团配备完善的生产管理组织架构，拥有丰 富经验的专业生产团队，与其生产设施相辅相成。 考虑到集团为满足自身临床试验及商业化而对药物生产的需求之外，集团可在适当的商机出现时更有效 利用富余产能。董事认为，订立CDMO服务框架协议将能更有效利用集团的富余产能，可为集团整体产 生补充现金流量。 格隆汇11月28日丨乐普生物-B(02157.HK)公告，于2025年11月28日，公司与乐普医疗订立CDMO服务框 架协议，据此，公司及╱或其附属公司同意向乐普医疗及╱或其附属公司提供CDMO技术服务。 ...